益气活血法联合介入治疗原发性肝癌疗效评价的Meta分析  

Meta-analysis of the efficacy of Yiqi Huoxue combined with interventional therapy for primary liver cancer

作　　者：魏亚威 高翔[2] 叶之华[2] 马利[3] WEI Ya-wei;GAO Xiang;YE Zhi-hua;MA Li(HuBei University cf Chinese Medicine( Wuhan Hubei,430065) China)

机构地区：[1]湖北中医药大学信息工程学院,湖北武汉430065 [2]湖北省中医院肝病研究所 [3]湖北中医药大学

出　　处：《中西医结合肝病杂志》2019年第3期250-253,共4页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：中国中医科学院基础所自主选题项目(No.YZ-1608)

摘　　要：目的:评价益气活血法联合介入治疗原发性肝癌的临床疗效,为其在临床应用提供循证医学依据。方法:计算机检索Pubmed、Cochrane Library、中国生物医学文献数据库、中国期刊全文数据库、重庆维普中文科技数据库和万方数据库6大数据库,全面搜集益气活血法联合介入治疗原发性肝癌的随机对照试验,用Jadad量表对纳入文献进行质量评价,提取资料并用RStudio 3.4.4软件进行Meta分析。结果:共纳入12篇随机对照文献,累计受试者947例,其中治疗组478例,对照组469例。Meta分析结果显示:益气活血法联合介入治疗可有效提高近期临床疗效([OR=2.76,95%CI[1.96;3.89],P<0.0001),改善生活质量(OR=4.04,95%CI[2.44,6.69],P<0.0001),1年生存期有显著提高(OR=2.06,95%CI[1.15,3.66],P=0.0145)。s结论:益气活血法联合介入治疗原发性肝癌有利于全面提高临床疗效,但本研究结论尚需纳入大样本、高质量的RCT进一步证实。Objective:To evaluate the efficacy of Yiqi Huoxue therapy combined with interventional therapy for primary liver cancer, and provide evidence-based medical basis for its clinical application;Methods:Computer search for Pubmed, Cochrane Library, China Biomedical Literature Database, China Journal Full-text Database, Chongqing Weipu Chinese Science and Technology Database and Wanfang Database 6 databases, comprehensive collection of Yiqi Huoxue method combined with interventional therapy for primary liver cancer.The Jadad scale was used to evaluate the quality of the included literature, and the data was extracted and analyzed by RStudio 3.4.4 software. Results:A total of 12 randomized controlled literatures were included, with a total of 947 subjects, including 478 in the treatment group and 469 in the control group.Meta-analysis results showed that Yiqi Huoxue combined with interventional therapy can effectively improve the short-term clinical efficacy([OR=2.76, 95%CI[1.96;3.89], P<0.0001) and improve quality of life(OR=4.04, 95% CI[ 2.44, 6.69], P<0.0001), the 1-year survival period was significantly improved(OR=2.06, 95% CI[1.15, 3.66], P=0.0145).Conclusion:Yiqi Huoxue combined with interventional therapy of primary liver cancer is beneficial to comprehensively improve clinical efficacy, but the conclusion of this study needs to be further confirmed by large sample and high quality RCT.

关 键 词：益气活血法 原发性肝癌 介入治疗 META分析 

分 类 号：R735.7[医药卫生—肿瘤]